Chronic myeloid leukemia as a stem cell-derived malignancy
Journal of Paramedical Sciences. 2012; 3 (2): 43-55
in English
| IMEMR
| ID: emr-195734
ABSTRACT
Chronic myeloid leukemia [CML] is a myeloproliferative disease of the hematopoietic stem cells, characterized by the presence of the Philadelphia [Ph] chromosome. Although imatinib inhibits the BCR-ABL kinase activity, clinical experiences confirm that imatinib may not target CML stem cells in vivo. The identification of signaling pathways responsible for the self-renewal properties of leukemic stem cells in CML will help in the discovery of novel therapeutic targets. Here we review signaling pathways including Wnt/beta-catenin, Hedgehog, Alox5, and Foxo which play crucial roles in the maintenance of stem cell functions in CML. It is thought that inhibition of key genes that are part of self-renewal associated signaling pathways may provide an effective way to reduce aberrant stem cell renewal in CML
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
J. Paramed. Sci.
Year:
2012
Similar
MEDLINE
...
LILACS
LIS